Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
People with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are at higher risk of developing infections due to having weakened immune systems.
MBL is a condition where there is an accumulation of abnormal B-cells in the blood. B-cells, also known as B-lymphocytes, are a type of white blood cell that makes antibodies to fight infections.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
Most people with chronic lymphocytic leukemia (CLL) at the time of diagnosis have no obvious symptoms and are often diagnosed based on the results of a routine blood test.
Receiving a cancer diagnosis is a challenging and emotional experience that can trigger a range of emotions including sadness, anxiousness, worry, anger, disbelief, denial, and confusion.
When the cancer is not causing significant health problems or bothersome symptoms and treatment is not yet needed
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
Measurable residual disease (MRD)-guided treatment of CLL with ibrutinib plus venetoclax significantly increased time in remission.
One click to our most popular content.
